Chia Tai Tianqing Pharmaceutical - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsChia Tai Tianqing Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Fosaprepitant dimeglumine	Fosaprepitant dimeglumine	2021-03-03		—
Fulvestrant	Fulvestrant	2020-02-07	2034	Breast neoplasms

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

healthy volunteers/patients

,

pharmacokinetics

,

,

non-hodgkin lymphoma

,

urinary bladder neoplasms

,

acrocephalosyndactylia

,

endometrioid carcinoma

,

peritoneal neoplasms

,

hereditary breast and ovarian cancer syndrome

,

malignant mesothelioma

,

,

pharmacological phenomena

,

,

,

digestive system neoplasms

,

neuroendocrine tumors

,

islet cell adenoma

,

urogenital neoplasms

,

female genital neoplasms

,

colonic neoplasms

,

ovarian neoplasms

,

endometrial neoplasms

,

non-small-cell lung carcinoma

,

prostatic neoplasms

,

ovarian epithelial carcinoma

,

colorectal neoplasms

,

squamous cell carcinoma of head and neck

,

uterine cervical neoplasms

,

,

,

fallopian tube neoplasms

,

castration-resistant prostatic neoplasms

,

pancreatic neoplasms

,

small cell lung carcinoma

,

ductal carcinoma

,

breast diseases

,

stomach neoplasms

,

,

brain neoplasms

,

hereditary sensory and autonomic neuropathies

,

carcinoma in situ

,

head and neck neoplasms

,

neoplasms by site

,

urologic neoplasms

,

uterine neoplasms

,

circulating neoplastic cells

,

intraductal carcinoma noninfiltrating

,

,

,

,

transitional cell carcinoma

,

squamous cell carcinoma

,

,

biliary tract neoplasms

,

adenocarcinoma of lung

,

serous cystadenocarcinoma

,

,

,

sex cord-gonadal stromal tumors

,

endometrial stromal sarcoma

,

,

,

pulmonary arterial hypertension

,

familial primary pulmonary hypertension

,

systemic lupus erythematosus

,

precocious puberty

,

polyostotic fibrous dysplasia

,

inborn genetic diseases

,

,

molecular targeted therapy

,

large b-cell lymphoma diffuse

,

salivary gland neoplasms

,

,

myxoid liposarcoma

,

esophageal squamous cell carcinoma

,

squamous cell neoplasms

,

,

spinocerebellar degenerations

,

,

,

male breast neoplasms

,

invasive hydatidiform mole

,

disease progression

,

lobular carcinoma

,

ductal carcinoma breast

,

neoadjuvant therapy

,

progression-free survival

,

cholangiocarcinoma

,

unilateral breast neoplasms

,

breast neoplasms

,

,

triple negative breast neoplasms

,

neoplasm metastasis

,

multiple endocrine neoplasia type 1

,

eye abnormalities

Eribulin mesylate

breast neoplasms

,

urologic neoplasms

,

urinary bladder neoplasms

,

transitional cell carcinoma

,

triple negative breast neoplasms

breast neoplasms

,

triple negative breast neoplasms

pharmacokinetics

colorectal neoplasms

,

endometrial neoplasms

biological availability

Efbemalenograstim alfa

,

non-small-cell lung carcinoma

,

,

febrile neutropenia

,

ovarian neoplasms

,

uterine cervical neoplasms

Aglatimagene besadenovec

prostatic neoplasms

,

,

breast neoplasms

,

pancreatic neoplasms

,

,

head and neck neoplasms

,

,

,

,

bile duct neoplasms

,

liver neoplasms

,

colonic neoplasms

,

squamous cell carcinoma

,

squamous cell neoplasms

,

1

2

3

4

5

6

>

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use